Identifying responsiveness to oral P2Y12 receptor blockers: Platelet function assays and genetic tests

Journal of Cardiovascular Medicine

Volumn 14, Issue SUPPL.1, 2013, Pages

  Valgimigli, Marco ^a  

^a UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

P2Y12receptor blockers; Platelet function test; Tailoring therapy

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; TIROFIBAN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANTICOAGULANT THERAPY; ANTIGEN ANTIBODY REACTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DRUG MEGADOSE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE FUNCTION ANALYZER; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANGIOPLASTY, BALLOON, CORONARY; BLOOD PLATELETS; DRUG MONITORING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84893299406     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e328364bd25     Document Type: Article

References (23)

1. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-offunction polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009; 30:916-922.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49:1505-1516. (Pubitemid 46517957)
3. Campo G, Fileti L, Valgimigli M, et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 2010; 30:319-331.
4. Aleil B, Jacquemin L, De Poli F, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008; 1:631-638.
5. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53:849-856.
6. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29:992-1000. (Pubitemid 351844676)
7. Patti G, Nusca A, Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDAPRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008; 52:1128-1133.
8. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119:237-242.
9. Campo G, Fileti L, de Cesare N, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 2010; 56:1447-1455.
10. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. Circulation 2009; 119:3215-3222.
11. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of onclopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
12. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative metaanalysis of individual participant data. J Am Coll Cardiol 2011; 58:1945-1954.
13. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305:1097-1105.
14. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003; 91:1123-1125. (Pubitemid 36514934)
15. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007; 115:708-716. (Pubitemid 46294761)
16. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19 - 2 allele on clopidogrel responsiveness. Thrombosis Res 2008; 121:463-468. (Pubitemid 351174278)
17. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelent reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drugeluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 2012; 59: Epub ahead of print (DOI: 10.1016/j.jacc.2012.1002.1026).
18. Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011; 306:1215-1223.
19. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010; 304:1821-1830.
20. Cayla G, Hulot JS, OConnor SA, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011; 306:1765-1774.
21. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312-1319.
22. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376:1320-1328.
23. Campo G, Valgimigli M, Frangione A, et al. Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. J Thromb Haemostasis2008; 6:1824-1826.